Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + methotrexate + pegfilgrastim
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This is a combination chemotherapy regimen with supportive care that includes three cytotoxic agents (cyclophosphamide, epirubicin, and fluorouracil), one antimetabolite (methotrexate), and a granulocyte colony-stimulating factor (pegfilgrastim). The combination of cyclophosphamide, epirubicin, and fluorouracil (CEF/FEC) is commonly used in breast cancer treatment, with pegfilgrastim added to reduce the risk of febrile neutropenia. Epirubicin is an anthracycline that inhibits DNA and RNA synthesis. Cyclophosphamide is an alkylating agent that cross-links DNA. Fluorouracil is an antimetabolite that interferes with DNA synthesis. Methotrexate inhibits dihydrofolate reductase. Pegfilgrastim stimulates neutrophil production to counteract chemotherapy-induced neutropenia.
02
Targets
DNADHFR (Dihydrofolate reductase)CSF3R (Granulocyte colony-stimulating factor receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)Neuraminidase
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + methotrexate + pegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + methotrexate + pegfilgrastim.